Drugs / HLA-matched VSTs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04013802 | Mar 2021 → May 2027 expected | viral infectious disease | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT07104591 | — | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection, disease related to hematopoietic stem cell transplant +1 | Baylor College of Medicine | Available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLA-matched VSTs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07104591 ↗ |
| Known as | Multivirus-specific Cytotoxic T Lymphocytes | “HLA-matched VSTs (Multivirus-specific Cytotoxic T Lymphocytes)” NCT07104591 ↗ |
| Modality | Cell therapy | “bank closely HLA-matched allogeneic VSTs” NCT04013802 ↗ |
| Route | Intravenous | “Partially HLA-matched VSTs will be thawed and given by intravenous injection.” NCT04013802 ↗ |